In his update on recent progress with pharmacological strategies for inhibiting ANGPTL3, 4, and 8 activity, Professor Sander Kersten describes research demonstrating effects on triglycerides and LDL-C and discusses the relevance of these and other findings for future management of cardiometabolic disease.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
